CHAPTER 1. INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2. RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3. MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4. MARKET DYNAMICS
4.1. Market Drivers & Opportunities
4.1.1. Increasing volume of surgeries and prevalence of severe trauma injuries.
4.1.2. Rising geriatric population.
4.1.3. Rising need for effective blood loss management in patients.
4.1.4. Strong focus on R&D leading to the launch of new and advanced products.
4.1.5. Untapped emerging markets.
4.2. Market Restraints & Challenges
4.2.1. The high price of biosurgery products & rising cost of surgical procedures.
4.2.2. Stringent regulatory framework.
4.2.3. The requirement of skilled personnel for the effective use of biosurgery products.
CHAPTER 5. GLOBAL BIOSURGERY MARKET – BY PRODUCT
5.1. Bone-Graft Substitutes
5.1.1 Demineralized Bone Matrix
5.1.2 Synthetic Bone Grafts
5.1.3 Bone Morphogenetic Proteins
5.1.4 Other Bone-Graft Substitutes
5.2. Soft Tissue Attachments
5.2.1.Synthetic Meshes
5.2.2. Biological Meshes
5.3. Surgical sealants and adhesives
5.3.1. Natural/Biological sealants and adhesives
5.3.2. Synthetic and semi-synthetic sealants and adhesives
5.4. Adhesion Barriers
5.4.1. Synthetic adhesion barriers
5.4.2. Natural adhesion barriers
5.5. Staple line reinforcement agents
5.6. Hemostatic agents
5.6.1. Combination Hemostatic Agent
5.6.2. Oxidized Regenerated Cellulose-Based Hemostatic Agents
5.6.3. Thrombin-Based Hemostatic Agents
CHAPTER 6. GLOBAL BIOSURGERY MARKET – BY APPLICATION
6.1. Orthopaedic Surgery
6.3 General Surgery
6.4 Neurological Surgery
6.5 Cardiovascular Surgery
6.6 Reconstructive Surgery
6.7 Gynecological Surgery
6.8 Urological Surgery
6.9 Thoracic Surgery
CHAPTER7. GLOBAL BIOSURGERY MARKET - BY GEOGRAPHY
7.1. Introduction
7.2. North America
7.2.1. U.S.
7.2.2. Canada
7.2.3. Mexico
7.2.4. Costa Rica
7.3. South America
7.3.1. Brazil
7.3.2. Argentina
7.3.3. Chile
7.3.4. Columbia
7.3.5. Others
7.4. Europe
7.4.1. U.K.
7.4.2. Germany
7.4.3. France
7.4.4. Italy
7.4.5. Spain
7.4.6. Russia
7.4.7. Netherlands
7.4.8. Switzerland
7.4.9. Poland
7.4.10. Others
7.5. APAC
7.5.1. China
7.5.2. Japan
7.5.3. India
7.5.4. South Korea
7.5.5. Australia & New Zealand
7.5.6. Malaysia
7.5.7. Singapore
7.5.8. Others
7.6. Middle East & Africa
7.6.1. UAE
7.6.2. Saudi Arabia
7.6.3. Iran
7.6.4. Iraq
7.6.5. Qatar
7.6.6. South Africa
7.6.7. Algeria
7.6.8. Morocco
7.6.9. Nigeria
7.6.10. Egypt
7.6.11. Others
CHAPTER 8. GLOBAL BIOSURGERY MARKET - COMPANY PROFILES
8.1. Baxter International, Inc.
8.2. B.Braun Melsungen AG
8.3. C.R. Bard Inc.
8.4. Johnson & Johnson
8.5. Medtronic, PLC.
8.6. MAQUET Holding B.V. & Co. Kg. (Getinge Group)
8.7. Cohera Medical Inc.
8.8. Integra Lifesciences Holdings Corporation
8.9. Commonwealth Serum Laboratories (CSL)
8.10. Hemostasis, LLC
8.11. Sanofi S.A.
8.12. Pfizer Inc.
8.13. Stryker Corporation
8.14. Cryolife, Inc.
CHAPTER 9. GLOBAL BIOSURGERY MARKET - COMPETITIVE LANDSCAPE
9.1. Market Share Analysis
9.2. Strategies adopted by top companies
9.3. Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 10. MARKET INSIGHTS
10.1. Industry Experts Insights
10.2. Analysts Opinions
10.3. Investment Opportunities
CHAPTER 11. APPENDIX
11.1. List of Tables
11.2. List of Figures
